|Table of Contents|

Clinical analysis of clinical characteristics,relationship between FISH test results and efficacy in patients with multiple myeloma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 02
Page:
307-311
Research Field:
Publishing date:

Info

Title:
Clinical analysis of clinical characteristics,relationship between FISH test results and efficacy in patients with multiple myeloma
Author(s):
GUO Mengyi; GAO Panke; LI Jingdong
Department of Haematology,the First Affiliated Hospital of Xinxiang Medical University,Henan Xinxiang 453100,China.
Keywords:
multiple myeloma; fluorescence in site hybridization; bortezomib
PACS:
R733.3
DOI:
10.3969/j.issn.1672-4992.2022.02.027
Abstract:
Objective：To explore the clinical characteristics,relationship between FISH test results and the efficacy of different treatment options in patients with newly treated multiple myeloma (MM).Methods:The clinical characteristics,FISH test results,treatment plan and curative effect of 54 patients with newly treated MM were retrospectively analyzed.The independent sample t test was used to compare the relationship between molecular genetics and patient clinical characteristics.χ2 test or Fisher to confirm the probabilistic method was used to compare the relationship between the efficacy of different treatment options and molecular genetic abnormalities.Results:The total response rate of 54 MM patients was 61.11%(33/54).Among the 41 patients who completed FISH test,70.73%(29/41) were accompanied by molecular genetic abnormalities,among which the detection rate of 1q21 amplification,del(13q14),del(p53),IgH translocation was 53.66%(22/41),31.71%(13/41),2.44%(1/41),36.59%(15/41).48.78%(20/41) of those had two or more abnormal genes.The serum corrected calcium level of del(13q14) positive patients was higher than that of negative patients (P＜0.05),and the proportion of bone marrow plasma cells of IgH translocation positive patients was higher than that of negative patients (P＜0.05).The total effective rate and complete response rate of patients with two or more molecular genetic abnormalities were lower than those with one molecular genetic abnormality (P=0.014,P=0.005).The effective rate of the patients with del(13q14) and 1q21 amplification positive in the traditional group was lower than that of the patients with negative (P=0.02,P=0.03).No difference was found between the IgH translocation positive and the IgH translocation negative (P＞0.05).There was no significant difference between the overall response rate of patients with abnormal gene and those with normal gene in bortezomib group (P＞0.05).Conclusion:The emergence of new therapeutic drugs has improved the efficacy of MM patients.Molecular genetic abnormalities are related to clinical features and efficacy,which can assist in judging the prognosis of patients and provide a basis for the selection of treatment options.Among them,13q14 deletion positive and 1q21 amplification are associated with poor treatment response.The proteasome inhibitor bortezomib can improve the short-term efficacy of patients with positive molecular genetics to a certain extent.

References:

[1] ZIOGAS DC,DIMOPOULOS MA,KASTRITIS E.Prognostic factors for multiple myeloma in the era of novel therapies［J］.Expert Rev Hematol,2018,11(11):863-879.
[2] HU Y,CHEN W,WANG J.Mutations in thirty hotspot genes in newly diagnosed chinese multiple myeloma patients［J］.Onco Targets Ther,2019,12:9999-10010.
[3] WANG Y,LI Q,XING S,et al.Clinical characteristics and prognosis of MAF deletion in Chinese patients with multiple myeloma［J］.Clin Lymphoma Myeloma Leuk,2019,19(9):e545-e550.
[4] 刘颖,陈建斌.伴1q21染色体扩增型多发性骨髓瘤治疗进展［J］.中国新药杂志，2019，28(11):1343-1347. LIU Y,CHEN JB.Advances in the treatment of multiple myeloma with chromosome 1q21 amplification［J］.Chinese Journal of New Drugs,2019,28(11):1343-1347.
[5]中国医师协会血液科医师分会,中华医学会血液学分会,中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2017年修订)［J］.中华内科杂志,2017,56(11):866-870. Chinese Hematology Association,Chinese Society of Hematology,Chinese Myeloma Committee-Chinese Hematology Association.The guidelines for the diagnosis and management of multiple myeloma in China ( 2017 revision )［J］.Chin J Intern Med,2017,56(11):866-870.
[6] RAJKUMAR SV,GREIPP PR.Prognostic factors in multiple myeloma［J］.Hematol Oncol Clin North Am,1999,13(6):1295-1314.
[7] SAXE D,SEO EJ,BERGERON MB,et al.Recent advances in cytogenetic characterization of multiple myeloma［J］.Int J Lab Hematol,2019,41(1):5-14.
[8] PUGH TJ,FINK JM,LU X,et al.Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice:An evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders［J］.Cancer Genet,2018,228-229:184-196.
[9] PAWLYN C,DAVIES FE.Toward personalized treatment in multiple myeloma based on molecular characteristics［J］.Blood,2019,133(7):660-675.
[10]王存邦,吴静,杨珂,等.多发性骨髓瘤遗传学异常的回顾性分析［J］.中国实验血液学杂志,2018,26(06):1681-1687. WANG CB,WU J,YANG K,et al.Retrospective analysis of genetics abnormalities in patients with multiple myeloma［J］.Journal of Experimental Hematology,2018,26(06):1681-1687.
[11]钟明星,何程明,黄继薇，等.CD138免疫磁珠细胞分选的FISH技术在多发性骨髓瘤诊断中的应用［J］.基因组学与应用生物学,2019,38(07):3243-3247. ZHONG MX,HE CM,HUANG JW,et al.Application of FISH technique in the diagnosis of multiple myeloma by CD138 immunomagnetizing beads［J］.Genomics and Applied Biology,2019,38(07):3243-3247.
[12] TABAYASHI T.Management of multiple myeloma in the relapsed/refractory patient［J］.Rinsho Ketsueki,2019,60(9):1257-1264.
[13] 郭彩玲.硼替佐米联合地塞米松、沙利度胺治疗多发性骨髓瘤的临床研究［J］.中国医刊,2019,54(12):1376-1379. GUO CL.Clinical study of bortezomib combined with dexamethasone and thalidomide in the treatment of multiple myeloma［J］.Chinese Journal of Medicine,2019,54(12):1376-1379.
[14]黄源,张慧.硼替佐米为主联合化疗方案与传统化疗方案治疗多发性骨髓瘤的疗效比较［J］.现代肿瘤医学,2020,28(01):117-120. HUANG Y,ZHANG H.Efficacy of chemotherapy combined with and without Bortezomid in the treatment of multiple myeloma［J］.Modern Oncology,2020,28(01):117-120.
[15] CHNG WJ,PRICE-TROSKA T,GONZALEZ-PAZ N,et al.Clinical significance of TP53 mutation in myeloma［J］.Leukemia,2007,21(3):582-584.
[16] LIEBISCH P,WENDL C,WELLMANN A,et al.High incidence of trisomies 1q,9q,and 11q in multiple myeloma:results from a comprehensive molecular cytogenetic analysis［J］.Leukemia,2003,17(12):2535-2537.
[17] SCHMIDT TM,BARWICK BG,JOSEPH N,et al.Gain of chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide,bortezomib,and dexamethasone［J］.Blood Cancer J,2019,9(12):94.
[18] FONSECA R,VAN WIER SA,CHNG WJ,et al.Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma［J］.Leukemia,2006,20(11):2034-2040.
[19] JIAN Y,CHEN X,ZHOU H,et al.Prognostic impact of cytogenetic abnormalities in multiple myeloma:a retrospective analysis of 229 patients［J］.Medicine (Baltimore),2016,95(19):e3521.
[20] CHEN LJ,LI JY,ZHU Y,et al.Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma［J］.Chinese Journal of Medical Genetics,2009,26(1):102-105.
[21] HEBRAUD B,MAGRANGEAS F,CLEYNEN A,et al.Role of additional chromosomal changes in the prognostic value of t(4;14) and del(17p) in multiple myeloma:the IFM experience［J］.Blood,2015,125(13):2095-2100.
[22] MERZ M,JAUCH A,HIELSCHER T,et al.Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma［J］.Blood Adv,2018,2(1):1-9.
[23] DUEK A,TRAKHTENBROT L,AMARIGLIO N,et al.Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16)［J］.Genes Chromosomes Cancer,2019,58(8):516-520.
[24] BYUN JM,SHIN DY,HONG J,et al.Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response:redefining high-risk multiple myeloma in Asian patients［J］.Cancer Med,2018,7(3):831-841.

Memo

Memo:
-
Last Update: 1900-01-01